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Identity 
Other names: R1; RIR1; RR1 
HGNC (Hugo): RRM1 
Location: 11p15.4 
Local order: STIM1 - RRM1 - OR55B1P - 
LOC643244. 
Note: The RRM1 gene is oriented on the plus strand. 
The chromosomal region containing the RRM1 gene 
locus displays frequent loss of heterozygosity (LOH) in 
lung cancer and is amplified in some instances of 
acquired resistance to gemcitabine and hydroxyurea. 
DNA/RNA 
Description 
The RRM1 gene consists of 44182 base pairs which 
encode 19 exons. 
Transcription 
The mature RRM1 mRNA is 3234 ribonucleotides in 
length and harbors an open reading frame of 2379 
ribonucleotides. 
Pseudogene 
There are no reported human RRM1 pseudogenes. 
Protein 
Note 
The RRM1 protein functions in a heterodimeric 
tetramer with either RRM2 (RRM2a) or p53R2 
(RRM2b) in the ribonucleotide reductase holoenzyme. 
While this interaction is essential for the de novo 
synthesis of deoxyribonucleotides, it is unclear whether 
this association is necessary for other biological 
activities ascribed to RRM1. 
Description 
The RRM1 protein is 792 amino acids in length and has 
a calculated molecular weight of 90 kDa. Analysis of 
the human RRM1 protein via the NCBI Conserved 
Domains program reveals an N-terminal ATP-cone 
domain and a Ribonucleotide Reductase (RNR) Class I 
domain which spans the majority of the protein. The 
RNR Class I domain harbors the all-alpha domain, the 
barrel domain, as well as regions and residues 
comprising the active site, the allosteric effector dTTP-
binding site, the RRM2 peptide-binding site and the 
dimer interface. 
Expression 
While the RRM2 subunit of the ribonucleotide 
reductase holoenzyme is regulated in a cell cycle-
specific manner, RRM1 expression remains relatively 
constant in actively proliferating cells. However, 
expression of RRM1 is significantly decreased upon 
exit from the cell cycle to G0 or terminal 
differentiation. This decreased level of RRM1 
expression in non-dividing cells is essential for the 
supply of dNTPs for mitochondrial DNA replication. 
Upregulation of RRM1 occurs when cells are 
stimulated to re-enter the cell cycle from G0. 
Localisation 
Depending on the experimental technique employed, 
the cell line or tissue sample, the cellular state and the 
antibody source, RRM1 can be detected within the 
nucleus, the cytoplasm or both. In quantitative 
immunofluorescent staining of non-small-cell lung 
cancer (NSCLC) cell lines and tumor samples, RRM1 
protein is predominantly nuclear. The method of 
analyzing nuclear RRM1 expression in resected 
NSCLC tumor samples can be used for survival 
prognostication. This is in agreement with fractionation 
of NSCLC cell lines, where RRM1 is detected almost 
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exclusively in the nuclear fraction. In contrast, studies 
utilizing various experimental methods to examine 
RRM1 in mouse and human lung fibroblasts find 
RRM1 to be cytoplasmic. This is in line with other 
studies that find RRM1 localized in cytoplasmic 
compartments in mouse fibroblasts, as well as 
cytoplasmic RRM1 immunoreactivity in various rat 
tissues. Still, another study demonstrates both nuclear 
and cytoplasmic RRM1 in multiple cell lines and finds 
RRM1 localized to the nuclear membrane, while others 
report a DNA damage-dependent relocalization of 
RRM1 from the cytoplasm to the nucleus. Given the 
current evidence, it is likely that RRM1 localization is 
dependent on cell type, tissue of origin, and cellular 
state. It is also evident that variables such as the 
antibody and experimental technique employed obscure 
a conclusive answer as to the true localization 
characteristics of RRM1. 
Function 
The RRM1 protein is implicated in 
deoxyribonucleotide (dNTP) synthesis, DNA damage 
response and repair and tumor suppression. In dNTP 
synthesis, RRM1 serves as the regulatory subunit of the 
ribonucleotide reductase (RR) holoenzyme, which 
catalyzes the de novo synthesis of dNTPs from 
ribonucleotide precursors. Synthesis of dNTPs via this 
pathway is reported to occur in the cytosol, with dNTPs 
re-localizing to the nucleus through diffusion and to the 
mitochondria via transport mechanisms. The RR 
enzyme primarily exists as a heterodimeric tetramer of 
RRM1 and RRM2, the primary catalytic subunit. While 
RRM1 expression remains relatively constant in 
cycling cells, RRM2 is regulated in a cell cycle-specific 
manner and is degraded upon exit from mitosis and 
absent in quiescent cells. Given this, the RRM2 subunit 
is the primary regulator of RR enzymatic activity. 
RRM1 can alternatively associate with the p53R2 
subunit in substitution for RRM2. Unlike RRM2, 
p53R2 is present in quiescent cells and as such 
associates with RRM1 under this context to provide 
dNTPs for mitochondrial DNA (mtDNA) replication in 
cells which are not actively dividing. Additionally, the 
expression of p53R2 is induced by the DNA damage 
response proteins p53 and p73, stabilized by ATM-
mediated phosphorylation and is reported to be 
involved in the supply of dNTPs by RR for mtDNA 
replication and DNA damage repair. The role of RRM1 
in the synthesis of dNTPs is also manifested as 
upregulation in cases of acquired resistance to 
gemcitabine and hydroxyurea, which directly inhibit 
the RR holoenzyme. 
In the context of DNA damage response and repair, 
stable overexpression of RRM1 in lung 
adenocarcinoma cells results in an increased fraction of 
cells arrested in G2/M. This coincides with increased 
expression of the GADD45 G2 checkpoint protein, 
which is thought to mediate this arrest. In response to 
DNA-damaging agents, overexpression of RRM1 
promotes the efficient repair of DNA damage. 
Additionally, RRM1-overexpressing cells have an 
increased level of apoptosis. When subjected to a 
murine chemical carcinogenesis protocol, mice 
transgenic for RRM1 (tg+) have significantly reduced 
lung tumor formation, and splenocytes derived from 
tg+ mice repair hydrogen peroxide-induced DNA 
damage more efficiently than those from tg- littermates. 
While the exact mechanism by which RRM1 
contributes to DNA damage response and repair in 
unclear, it may involve its association with the p53R2 
RR subunit. This subunit is induced by the DNA 
damage responsive p53 and p73 transcription factors, is 
stabilized by ATM-mediated phosphorylation and can 
substitute for RRM2 in the RR complex. Current data 
indicates a role for p53R2 in providing dNTPs during 
DNA damage repair and may explain the involvement 
of RRM1 in DNA damage response and repair. 
With regard to tumor suppression, overexpression of 
RRM1 in human and mouse lung cancer cell lines, as 
well as ras-transformed mouse fibroblasts, inhibits 
metastasis, tumorigenicity and motility. It also 
suppresses metastasis formation and increases survival 
in a syngeneic murine lung cancer model. Evidence 
points to reduced phosphorylation of focal adhesion 
kinase (FAK) and increased PTEN expression as 
mediators of these effects. Mice transgenic for RRM1 
subjected to a murine chemical carcinogenesis protocol 
display significantly decreased lung tumor 
development and survive significantly longer than tg- 
littermates. Additionally, multiple clinical studies show 
correlations between increased intratumoral RRM1 
expression in surgically resected tumor tissue and 
increased survival (NSCLC, pancreatic cancer, bladder 
cancer). As previously noted, reduced FAK 
phosphorylation and increased PTEN expression are 
thought to be the primary mediators of the tumor 
suppressor function of RRM1; however, the ability of 
RRM1 to contribute to DNA damage response and 
repair may also play a role. 
Homology 
The RRM1 protein is highly conserved from human to 
many lower organisms. Human RRM1 protein shares 
99.7% similarity and 97.6% identity with mouse (M. 
musculus) RRM1 and 88.2% similarity and 69.1% 
identity with that of fission yeast (S. pombe). It does 




At this point, there are no described germline mutations 
within the RRM1 gene. There are a total of 272 
reported single nucleotide polymorphisms (SNPs) for 
the RRM1 gene. Nine are in the coding region of 
RRM1, and four result in amino acid alterations which 
consist of: G249A, A768C, T821G and T2565C. We 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(5)  475 
sequenced the genomic region of RRM1 and deposited 
this data in GenBank (AF107045), which provided for 
the reference for some of the reported SNPs. In 
addition, we described SNPs in the RRM1 promoter 
region that have a substantial effect on in vitro reporter 
gene transcription. 
Somatic 
RRM1 resides at 11p15.5, a frequent region of allele 
loss in cancer. Additionally, amplification of RRM1 
has been observed in acquired resistance to 
gemcitabine and hydroxyurea. 
Implicated in 
Non-small cell lung cancer (NSCLC) 
Note 
Overexpression of RRM1 in human and mouse lung 
cancer cell lines inhibits motility in cell culture and 
decreases metastasis and tumorigenicity in a syngeneic 
mouse lung cancer model. Increased survival is also 
noted upon RRM1 overexpression in the same model. 
Mice transgenic for RRM1 subjected to a chemical 
carcinogenesis protocol display significantly decreased 
lung tumor development and survive significantly 
longer than tg- littermates. 
Since gemcitabine works in part through the inhibition 
of ribonucleotide reductase, RRM1 is a key molecule 
involved in the therapeutic response. Multiple NSCLC 
clinical studies demonstrate that while decreased 
intratumoral RRM1 is indicative of sensitivity to 
gemcitabine, elevated levels are predictive of poor 
response to gemcitabine. In NSCLC cell lines, 
depletion of RRM1 results in sensitivity to 
gemcitabine, and vice versa increased RRM1 
expression results in resistance to gemcitabine. 
Gemcitabine-resistant NSCLC cells display 
upregulation of RRM1, and depletion of RRM1 in 
these cells restores gemcitabine sensitivity. 
Additionally, a 2464G>A RRM1 polymorphism was 
reported to be associated with gemcitabine sensitivity 
in cancer cell lines of various origins, while NSCLC 
patients harboring a combination of the RR37AC and 
RR524CT promoter polymorphisms, the haplotype 
associated with decreased promoter activity, show 
greater response to gemcitabine. 
Disease 
NSCLC is the most frequently diagnosed type of lung 
cancer and refers to malignant neoplasms of the lung 
which are histologically distinct from small cell lung 
cancer. NSCLC cases are classified as adenocarcinoma, 
large cell carcinoma or squamous (epidermoid) 
carcinoma. The National Cancer Institute (NCI) 
estimates that there were 215,020 new cases of lung 
cancer and 161,840 deaths in 2008. 
Prognosis 
Loss of the chromosomal region harboring RRM1 in 
NSCLC is associated with increased metastatic spread 
and decreased overall survival (OS) in patients with 
stage I or stage II disease. RRM1 mRNA derived from 
surgically resected NSCLC tumors indicates that high 
levels of RRM1 expression are associated with longer 
survival. This result was confirmed in a study where an 
elevated level of intratumoral RRM1 protein was 
prognostic of favorable survival. In addition to RRM1 
expression, promoter polymorphisms at positions -37 
and -524 (RR37AC and RR524CT), which regulate 
RRM1 expression in in vitro models, are associated 
with survival. 
Cytogenetics 
The RRM1 gene resides at 11p15.5, a region frequently 
associated with allele loss in NSCLC. This is 
exemplified in primary lung cancer tissue as well as 
lung cancer cell lines. The region of minimal allele loss 
in NSCLC is mapped to a 310 kb region which contains 
the complete coding sequence for the RRM1 and 
SSA/Ro52 genes. Of these two genes, RRM1 is 
identified as the putative tumor suppressor within this 
region of LOH. 
Pancreatic cancer 
Note 
Increased RRM1 expression is indicative of resistance 
to gemcitabine in pancreatic cancer. RRM1 is the most 
highly upregulated gene observed in the 81-fold 
gemcitabine-resistant MiaPaCa2 derived cell line 
MiaPaCa2-RG, and siRNA depletion of RRM1 
expression in this resistant cell line restores 
gemcitabine sensitivity. During the acquisition of 
gemcitabine resistance in pancreatic cell lines, 
progressive upregulation of RRM1 is observed. 
Disease 
The term pancreatic cancer refers to malignant 
neoplasms of the pancreas. Tumors of the pancreas can 
originate from either exocrine or endocrine pancreatic 
cells, with exocrine pancreatic cancer being the 
predominant form. The majority of exocrine pancreatic 
cancers are adenocarcinomas. The NCI estimates that 
there will be 42,470 new cases of pancreatic cancer and 
35,240 deaths in 2009. 
Biliary tract cancer 
Note 
Depletion of RRM1 expression via siRNA in the G-415 
biliary tract carcinoma cell line increases sensitivity to 
gemcitabine and enhances gemcitabine-induced 
apoptosis. Tumor tissue derived from biliary tract 
carcinoma patients treated with gemcitabine shows a 
tendency toward elevated RRM1 expression 
associating with progressive disease (PD) and 
decreased RRM1 expression associating with partial 
response (PR), although these tendencies were not 
statistically significant. These results suggest that 
RRM1 expression may be a useful tool for predicting 
response to gemcitabine in patients with cancer of the 
biliary tract. 
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Disease 
Biliary tract cancer refers to malignant neoplasms of 
the gallbladder and/or bile duct. Cancers of the bile 
duct are referred to as cholangiocarcinomas, while 
other cancers of the biliary system include gallbladder 
cancers and cancer of the ampulla of Vater. Biliary 
tract malignancies are relatively rare. 
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